This study aimed to evaluate the efficacy and the safety of the anti-programmed-death-1
antibody (anti-PD-1) Sintilimab Injection in combination with transarterial chemoembolization
with drug-eluting beads(TACE-DEB) in patients with early and intermediate stage
hepatocellular carcinoma (HCC) who isn't suitable for primary surgical resection.